Loading...
Argenica Therapeutics Limited
AGN.AX•ASX
Healthcare
Biotechnology
A$0.67
A$-0.01(-1.47%)
Argenica Therapeutics Limited (AGN.AX) Financial Performance & Income Statement Overview
Review Argenica Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
48.46%
↑ 48.46%
Operating Income Growth
14.40%
↑ 14.40%
Net Income Growth
-13.80%
↓ 13.80%
Operating Cash Flow Growth
-53.34%
↓ 53.34%
Operating Margin
-184.14%
↓ 184.14%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-170.72%
↓ 170.72%
ROE
-38.73%
↓ 38.73%
ROIC
-42.98%
↓ 42.98%
Argenica Therapeutics Limited (AGN.AX) Income Statement & Financial Overview
Review Argenica Therapeutics Limited's (AGN.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $122756.00 | $122756.00 | $1.18M | $1.18M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $122756.00 | $122756.00 | $1.18M | $1.18M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $1.60M | $1.60M | $2.82M | $1.41M |
| SG&A Expenses | $629052.00 | $629052.00 | $994283.00 | $497142.00 |
| Operating Expenses | $2.23M | $2.23M | $3.81M | $1.91M |
| Total Costs & Expenses | $2.23M | $2.23M | $3.81M | $1.91M |
| Interest Income | $140317.00 | $0.00 | $51768.00 | $25739.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $2.11M | $2.11M | $730517.00 | $730517.00 |
| EBITDA | -$1.96M | $0.00 | -$2.80M | $25739.00 |
| EBITDA Ratio | -$16.006 | $0.00 | -$3.24 | $0.02 |
| Operating Income | -$2.11M | -$2.11M | -$3.81M | -$730517.00 |
| Operating Income Ratio | -$17.15 | -$17.15 | -$3.24 | -$0.62 |
| Other Income/Expenses (Net) | -$1.96M | $70120.00 | $282594.00 | $25739.00 |
| Income Before Tax | -$4.07M | -$2.03M | -$3.53M | -$704778.00 |
| Income Before Tax Ratio | -$33.15 | -$16.58 | -$3.002 | -$0.60 |
| Income Tax Expense | -$2.03M | $0.00 | -$2.12M | $25739.00 |
| Net Income | -$2.03M | -$2.03M | -$1.41M | -$704778.00 |
| Net Income Ratio | -$16.58 | -$16.58 | -$1.20 | -$0.60 |
| EPS | -$0.02 | -$0.02 | -$0.01 | -$0.007 |
| Diluted EPS | -$0.02 | -$0.02 | -$0.01 | -$0.007 |
| Weighted Avg Shares Outstanding | $107.70M | $107.70M | $99.15M | $99.26M |
| Weighted Avg Shares Outstanding (Diluted) | $108.15M | $108.15M | $99.15M | $99.26M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan